Articles

• All
• CVD
• CKD
• Dialysis
• SGLT2i
• Hypertension
• Hyperglycaemia
• AKI
• RAAS
• Anaemia
• Transplantation

• 

  SGLT2i kidney outcome trial participants vs a real-world population

  11 May 2024

  • SGLT2i
  • CKD
  • Hyperglycaemia

• 

  SGLT2 inhibitors versus GLP-1 receptor agonists for renal patients: does it matter?

  14 Mar 2024

  • SGLT2i
  • Hyperglycaemia
  • Editorial

• 

  Novel antidiabetes drugs improve composite renal outcomes

  13 Mar 2024

  • CKD
  • Hyperglycaemia
  • SGLT2i

• 

  Pharmacotherapy for weight management in HFpEF: Do we have to lose big to win small?

  9 Oct 2023

  • CVD
  • SGLT2i
  • Editorial

• 

  Dapagliflozin and cardiovascular risks with worsening renal function

  7 Oct 2023

  • CKD
  • CVD
  • SGLT2i

• 

  Cardiorenal biomarkers in the CREDENCE trial

  6 Oct 2023

  • CKD
  • CVD
  • SGLT2i

• 

  Glucose-lowering medications and comparative kidney outcomes in type 2 diabetes

  27 Jun 2023

  • Hyperglycaemia
  • SGLT2i

• 

  Sodium–glucose cotransporter 2 inhibitors in heart failure: does it matter how they work?

  16 May 2023

  • SGLT2i
  • CVD
  • Editorial

• 

  EMPA-VISION: Cardiac energy in people with heart failure taking empagliflozin

  15 May 2023

  • SGLT2i
  • CVD